Neuroscience Education Series - Chimeric Antigen Receptor (CAR) T-Cell Therapy Related Neurotoxicity

Wednesday, February 19, 2025, 1:00 PM - Saturday, February 19, 2028, 2:00 PM

ANCC Nursing Contact Hours (1.00 hours), General Attendance (1.00 hours)

This educational activity is intended to address the knowledge gaps surrounding the management of CAR T-Cell therapy and identifying complications.

Presenter

John Hill, MD
Hematology/Oncology
Dartmouth Hitchcock Medical Center

1. Discuss the rationale, immunology and clinical components related to the implementation of CAR T-Cell Therapy.
2. Identify potential signs and symptoms of Neurotoxicity (ICANS) following CAR T-Cell Therapy, along with grading and management.
3. Recognize the collaboration needed between Neurology/Neuro-ICU and the Transplant and Cellular Therapy Team in the management of CAR T patients.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours. 

All other learners may claim General Attendance credit. Consult your professional licensing board regarding the applicability and acceptance of General Attendance credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.

2. Register for the activity.

3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.

4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).

5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.

6. Complete and Submit the Evaluation.

Bibliographic Sources

• Belin C, Devic P, Ayrignac X, et al. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy. Sci Rep. 2020;10(1):18997. doi:10.1038/s41598-020-76055-9

  
  

• Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi:10.1016/j.bbmt.2018.12.758

  
  

• Herr MM, Chen GL, Ross M, et al. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score. Biol Blood Marrow Transplant. 2020;26(11). doi:10.1016/j.bbmt.2020.07.031

  
  

• Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P. Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplantation and Cellular Therapy. 2021 Nov 1;27(11):930-e1.

  
  

• Karschnia P, Jordan JT, Forst DA, et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019;133(20):2212-2221. doi:10.1182/blood-2018-12-893396

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
clpd.support@hitchcock.org

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.